Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial ...

(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency INB-619, a next generation γδ TCE targeting CD19 ...

In8bio Inc. has unveiled INB-600, its next-generation γδ T-cell-based T-cell engager (TCE) platform designed to address one of the shortcomings of current existing γδ TCEs, specifically insufficient ...

Preliminary pharmacokinetic and pharmacodynamic data were consistent with the PROBODY TCE mechanism of action, including maintained masking in circulation, and CD8+ T-cell margination and tumor ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. This time, the pharma is paying Xilio Therapeutics $52 million upfront to work on antibody-based ...

Genrix’s velinotamig complements Cullinan’s own pipeline, according to William Blair, which added that the deal will put ...

JANX’s proprietary Tumor-Activated T Cell Engager [TRACTr] and Tumor-Activated Immunomodulator [TRACIr] platforms engineer drug candidates designed to overcome the limitations of existing T-cell ...

The FDA cleared an investigational new drug application for CLN-978, a bispecific T cell engager, allowing for a phase 1 trial in patients with active, moderate-to-severe SLE. According to the ...